Multicenter, randomized, placebo- controlled, double blind study of HS219 to evaluate the efficacy and safety in chronic kidney disease patients on hemodialysis with hyperphosphatemia - Study of HS219 in chronic kidney disease patients on hemodialysis with hyperphosphatemia
100 项与 Healthserve Ltd. 相关的临床结果
0 项与 Healthserve Ltd. 相关的专利(医药)
100 项与 Healthserve Ltd. 相关的药物交易
100 项与 Healthserve Ltd. 相关的转化医学